Hasil untuk "Neoplasms. Tumors. Oncology. Including cancer and carcinogens"

Mengyao Tang, Lanlan Chen

Abstract Mendelian Randomization (MR) is increasingly used in cancer research to infer causal relationships by leveraging genetic variants as instrumental variables. While the growth of genome-wide association studies and biobank data has expanded the utility of MR, this surge—particularly pronounced in China—raises concerns about methodological rigor. The widespread adoption may be partly driven by the Chinese translation of key MR literature. Recent advances such as multivariable MR, mediation analysis, and integration with AI and omics data have enhanced the robustness and biological interpretability of MR studies. However, challenges persist, including horizontal pleiotropy, weak instrument bias, and misinterpretation of biomarkers as causal exposures. To improve MR study credibility, frameworks like STROBE-MR and MR-GRADE are being adopted. This article reviews methodological improvements and persistent pitfalls in MR, especially within cancer epidemiology, and highlights strategies for ensuring validity in this rapidly evolving field.

Prashasti Agrawal, MD, Michael Offin, MD, Victoria Lai, MD et al.

Introduction: WT1 often presents on the surface of diffuse pleural mesotheliomas (DPMs) and is an ideal therapeutic target. Galinpepimut-S (GPS), a tetravalent, non–human leukocyte antigen–restricted, heteroclitic WT1–specific peptide vaccine was safe and effective in early phase clinical trials and upregulates T-cell suppressive programmed death-ligand 1 in the tumor microenvironment of other malignancies. A randomized phase 2 study of adjuvant GPS in patients with DPM trended toward improved median overall survival. Methods: To further enhance immunogenicity, we combined GPS with nivolumab, an anti-PD1 monoclonal antibody, in an open-label, single-center phase 1 study, examining tolerability and immunogenicity in patients with previously treated DPM. We enrolled patients with progressive or recurrent DPM treated with at least one course of pemetrexed-based chemotherapy. Patients received two doses of GPS followed by six doses of GPS with intravenous nivolumab every 2 weeks, and up to six additional cycles until disease progression or unacceptable toxicity. Results: Ten patients were treated; 70% experienced mostly mild treatment-related adverse events; two experienced a grade 3 or higher adverse event. Three of the 10 patients (30%) reported vaccine-specific T-cell responses. There were no partial responses; three patients had prolonged stable disease with up to 17% decrease in tumor volume. Median progression-free survival was 3.9 months and the median overall survival was 7.4 months. Conclusions: Coadministration of GPS and nivolumab reported a tolerable toxicity profile and induced immune responses in a subset of patients, but initial response and survival benefit were limited possibly owing to the small sample size.

A. Yusupova, R. Yusupova, E. Egorova

Colorectal cancer (CRC) is the third most common and second most lethal cancer in the world. In most countries, including Russia, the number of new cases of CRC continues to grow and may reach 2.2 million by 2030. The favorable prognosis when starting treatment for the disease in the early stages is very high, which makes screening programs for CRC cost-effective. Since 2020, a new laboratory research method has been actively introduced in Russia: the determination of human hemoglobin and transferrin in feces, which makes it possible to diagnose diseases of the gastrointestinal tract. Quantitative determination of human hemoglobin and transferrin in feces is carried out to detect gastrointestinal bleeding of any etiology. Based on the concentration of the determined substances and their ratio, this test allows you to identify intestinal polyps and various forms of colorectal cancer, as well as clearly determine the need for colonoscopy for each specific patient. Diagnostic colonoscopy is performed for the purpose of screening (that is, examining the patient before complaints appear), malignant neoplasms, or precancerous diseases of the colon. During the study, the frequency of detection of adenomas, polyps, and colorectal cancer was assessed. Statistical processing of the data obtained consisted of statistical observation of the results of a stool test for occult blood exceeding the reference value (50 ng/ml or more). Automatic analyzers are highly sensitive, making it possible to diagnose the disease already at the initial stages of the disease. Also in 2020, the oncology service of Bashkortostan switched to a new analytical two-marker system. If hemoglobin is present, we can talk about a problem in the lower parts of the intestine, but if transferrin is present, we can talk about a higher-lying tumor.

Fira Soraya, Willy Sandhika

Introduction: Soft tissue tumors account for 1 – 1.5% of all cancer, which is the tenth most common cancer in referral oncology hospitals in Indonesia. Liposarcomas are a group of histologically diverse lesions, accounting for 12.8% – 20% of all soft tissue malignancies. Some soft tissue tumors may show similar histological appearance, making differentiating mesenchymal neoplasms a difficult challenge. Immunohistochemical examination is an advanced examination to refine and determine the diagnosis that cannot be established based on histopathological examination only. Methods: This study was an observational descriptive study with a retrospective approach. The data of patients with liposarcoma was obtained from immunohistochemistry examination results in Dr. Soetomo General Academic Hospital during 2020 – 2022 period, which includes the histopathology result. All cases were classified based on WHO. We considered only patients with immunohistochemistry examination proven diagnosis who underwent surgery or biopsy in the same institution. Results: The total number of liposarcoma cases was 20, with most patients were male (90%) and age group 40 – 49 years old (30%). The most common location was the abdominal region (55%), including intra-abdominal, mesentery, and retroperitoneal. The most common subtype was dedifferentiated liposarcoma with 10 cases (50%). Conclusions: Immunohistochemistry examination in malignant adipocytic tumors aims to confirm the diagnosis, with the most common subtype being dedifferentiated liposarcoma. It is necessary to consider the morphology in H&E staining together with the immunohistochemistry profile as well as all clinical and radiology information to establish the most relevant diagnosis.

Mahmoud Kassem, Ahmed Kamr, Creighton B. Wright et al.

Objective: Breast conserving surgery is an excellent option in the treatment of breast cancer. To achieve a good result with this modality, a surgeon needs to identify and excise the tumor with adequate margins. The radiofrequency identification (RFID) technique is a wireless localization technique used for intraoperative breast lesion identification. We assessed the efficacy and outcomes of the RFID technique in breast cancer patients at our institution. Materials and Methods: This is a single institution, retrospective study (BSMH 22-02X-MWH) of 73 patients. We analyzed the medical records of women with biopsy-proven breast cancer from June 2020 to August 2022; participants received surgical care at Mercy Health West Hospital. Data collected included demographics, clinicopathological characteristics, and surgical procedure. The primary objective was to determine the safety and efficacy of RFID. The secondary objective was to assess the impact of obesity and breast density on the RFID outcomes. Results: A total of 73 female patients met the eligibility criteria with stage I (59%) and grade 1 (51%) breast cancer with mean age of at diagnosis of 66.8 years and mean body mass index of 31.4 kg/m2. Patients had invasive ductal carcinoma (61%), hormonal positive (56%), and human epidermal growth factor receptor 2 negative (68%) disease. All RFID tags were placed under image guidance with 100% accuracy of placement with no evidence of migration or procedure revision. Ninety percent of patients had free surgical margins and only seven patients needed margin re-excision with successful removal of the lesion and the tag. Conclusion: RFID localization technique is a safe, effective and reliable procedure that results in favorable patient outcomes and quality of life.

Ek Leone Oh, Wade Huish, Sara El-Gamil et al.

Background and objective: It is widely accepted that the value of treatments for incurable metastatic cancer depends on their ability to improve overall survival (OS), quality of life (QoL), or both. Progression-free survival (PFS) is frequently used as a primary endpoint because of challenges in accurately assessing OS and QoL. The perceived value of extending PFS when there is uncertainty regarding the benefit to OS/QoL may vary between clinicians and patients. The aim of our study was to measure patient and clinician perspectives on what defines a clinically meaningful PFS benefit. Methods: We conducted an observational study using a self-administered questionnaire. Participants included patients with advanced prostate cancer (PC) and medical oncology clinicians treating patients with PC. The questionnaire presented a hypothetical scenario of metastatic castrate-resistant PC (mCRPC). Participants were asked about their willingness to undergo or prescribe treatment offering PFS benefits despite uncertain OS outcomes. Participants specified the minimum extension of PFS (ePFSmin) beyond the estimated 18-mo duration outlined in the scenario while considering varying toxicity levels. Key findings and limitations: Between April and May 2024, 54 patient responses and 27 clinician responses were received. Some 50/54 patient participants (92.6%) and 22/27 clinician participants (81.5%) expressed willingness to accept a prospective treatment associated with longer PFS but uncertain OS benefit. For treatment with no or mild toxicity, the median ePFSmin for treatment acceptance was >12 mo for patient participants and 3–6 mo for clinician participants. For treatment with severe toxicity, 40.7% of patients and 51.9% of clinicians would not accept treatment; the ePFSmin for treatment acceptance was 3–6 mo for patient participants and >12 mo for clinician participants. Conclusions and clinical implications: Most patients and clinicians are open to mCRPC treatment with evidence of PFS benefits despite OS uncertainty. Patients needed longer PFS extension to justify treatment but were more accepting of side effects and placed greater importance on a prostate-specific antigen or radiological response than clinicians. The relationship between ePFSmin and treatment acceptance according to toxicity levels for patients was unclear, limited by the nature of the self-administered questionnaires. Patient summary: We surveyed patients and doctors about their views on an imaginary treatment for advanced prostate cancer that could delay disease progression but with no certainty about whether it would extend life expectancy. Both patients and doctors were open to this treatment, but patients expected a longer delay in disease progression than doctors before being willing to accept this imaginary treatment. Many patients and doctors would also not consider the treatment if it caused severe side effects.

Olumide Arigbede, Gebre-Egziabhe Kiros

Objective: We aim to investigate indicators of risk for invasive breast cancer (IBC) and to predict and assess the impact of these risk indicators on survival rates in breast cancer (BC) patients who received various therapies. Background: It has been identified that several indicators including BC subtypes, age at diagnosis, history of breast disease, menopausal status, estrogen receptor (ER) status, progesterone receptor (PR) status, human epidermal growth receptor (HER2) status, tumor stage, tumor size, among others, can cause genomic alterations and driver mutations in BC, leading to invasive carcinogenesis. To assure improved BC outcomes, we investigate the influence of BC indicators on survival rates in patients receiving hormone therapy, chemotherapy and radiotherapy. Methods: This study uses the Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) dataset, which included 31 clinical indicators, m-RNA levels z-score for 331 genes, and mutation in 175 genes for 1904 BC patients. Both bivariate and multivariate associations were examined using logistic regression and Cox proportional hazard models. The multivariate logistic regression analysis is used to determine predictors of IBC. The Cox proportional hazard model was also used to evaluate the magnitude of the impacts of clinical and demographic variables on IBC, as well as the effects of therapy on survival. All analyses for this investigation were carried out using SAS. A p-value < 0.05 was considered statistically significant. Results: We examined 1,043 patients (with the median age 61±13.1 years) from a total of 1904 for this study: 78.8% of patients had breast invasive ductal carcinoma; 87.4% were HER2 negative; 22.8%, 60.7%, and 67.6% received chemotherapy, hormone therapy, and radiotherapy treatments, respectively; 56.9% died but only 34.6% died from the disease; the average overall survival months was 127.3±77.6 months; and the most common age group was "65+ years" (39.4%). Chemotherapy (p=0.0474), neoplasm histologic grade (p=0.0015), Nottingham prognostic index (p<.0001), radiation (p=0.0068), and BReast CAncer gene 1 (BRCA1) (p=0.0251) were all associated with IBC. Overall survival was also correlated to age at diagnosis (p=0.0002), neoplasm histologic grade (p<.0001), lymph nodes (p<.0001), mutation count (p<.0001), Nottingham prognostic index (p<.0001), radiotherapy (p=0005), tumor size (p<.0001), tumor stage (p<.0001), BRCA1 (p=0.250), PTEN (p<.0001), and TP53 (p=0.0248). The overall accuracy of the model for each IBC and survival status was 82.1% and 74.2%, respectively. Conclusion: Our analysis demonstrated the importance of predictive analysis using the logistic regression model and survival analysis using the Cox proportional hazard model in cancer research. Predictive and survival analysis results aided in predicting the invasiveness and survival rate of BC among the study participants. In general, predictive and survival analyses are more accurate and may be used to make more realistic treatment decisions and precision oncology. Citation Format: Olumide Arigbede, Gebre-Egziabhe Kiros. Analysis of predictive indicators of invasive breast cancer: Modeling survival rates [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Translating Cancer Evolution and Data Science: The Next Frontier; 2023 Dec 3-6; Boston, Massachusetts. Philadelphia (PA): AACR; Cancer Res 2024;84(3 Suppl_2):Abstract nr B042.

V. Loginov, M. Gubenko, A. Burdennyy et al.

Objectives. Lung cancer, representing a difficult-to-diagnose heterogeneous malignant neoplasm, is characterized by an asymptomatic course up to late stages, a high incidence of adverse outcomes, and a high probability of metastasis. Its most common form is non-small cell lung cancer (NSCLC). Recent studies have demonstrated a significant role of non-coding RNAs—in particular, microRNAs—in the development of NSCLC. MicroRNAs, which function as post-transcriptional regulators of the expression of protein-coding genes, including those associated with oncogenesis, are involved in the processes of cell proliferation, differentiation, and apoptosis. One of the approaches for regulating the expression of microRNAs themselves is to change the methylation of the CpG island adjacent to the microRNA gene or overlapping it. It has been shown that microRNA genes are several times more likely to undergo methylation than protein-coding genes. The aim of the present work is to study changes in the level of methylation of a number of microRNA genes and compile a potential panel of markers for the diagnosis and prognosis of NSCLC.Methods. Samples of NSCLC tumors were collected and clinically characterized at the Blokhin National Medical Research Center of Oncology, Ministry of Health of the Russian Federation, Moscow, Russia. High-molecular-weight DNA was isolated from tissues using a standard method. The level of methylation was analyzed using bisulfite conversion of DNA and quantitative methyl-specific polymerase chain reaction with real-time detection. The significance of differences between the studied groups was assessed by the nonparametric Mann–Whitney U test for independent samples. Differences were considered significant at p < 0.05.Results. The analysis of methylation levels of microRNA genes revealed a significant (p < 0.05) increase in the methylation level of eight microRNA genes: MIR124-1/2/3, MIR125В-1, MIR129-2, MIR137, MIR375, MIR1258, and MIR339 (p < 0.01, false discovery rate ≤ 0.25). On the basis of receiver operating characteristic analysis, a panel of markers is proposed for the diagnosis of NSCLC according to the nature of methylation of the studied microRNA genes in the tumor and in the normal tissue.Conclusions. Our results, which contribute to the understanding of molecular mechanisms involved in NSCLC development, can be used in the development of new diagnostic and prognostic approaches in clinical oncology.

S. Elhabashy, M. Wahdan, Doha Hussein et al.

Currently, timely diagnosis immediately followed by effective treatment is an essential approach for control of the public health burden due to childhood cancers. Our aim was to ascertain the median lag time till diagnosis, and treatment of pediatric patients with malignancy and to determine factors influencing the delayed diagnosis and relate delay times to diagnosis with overall and event free survival rates. A cross sectional prospective study including children and adolescents with confirmed cancer diagnosis was conducted in Pediatric Hematology –Oncology Unit of Ain Shams University Children's Hospital, Egypt. A predesigned questionnaire was structured to collect data from parents or legal guardians of patients diagnosed with cancer about demographic and cancer characteristics the latter included presenting symptoms, type, site, risk, modalities of diagnosis, time to diagnose, treatment with calculation of event free survival and overall survival times. The study enrolled 115 children and adolescents with cancer during the period from August 2020 to May 2021. Misdiagnosis was initially recorded in 16 (13.9%) patients. Median total diagnostic delay or Lag Time (LT) for all patients was 53 days. Patients’ gender, age and socioeconomic status did not affect the median total delay, whereas residency, misdiagnosis, presence of health insurance, tumor location and presence of metastasis significantly influenced the total diagnostic delay. There was no significant correlation between overall and event free survival rates and total diagnostic delay. Delayed diagnosis of solid malignant neoplasms except Wilms tumor, needs more attention to health care providers awareness especially in rural regions.

Xuanzhao Chen, Zeyan Li, Meihua Liang et al.

Abstract Background Triple-negative breast cancer (TNBC) is the most heterogenous and aggressive subtype of breast cancer. Chemotherapy remains the standard treatment option for patients with TNBC owing to the unavailability of acceptable targets and biomarkers in clinical practice. Novel biomarkers and targets for patient stratification and treatment of TNBC are urgently needed. It has been reported that the overexpression of DNA damage-inducible transcript 4 gene (DDIT4) is associated with resistance to neoadjuvant chemotherapy and poor prognosis in patients with TNBC. In this study, we aimed to identify novel biomarkers and therapeutic targets using RNA sequencing (RNA-seq) and data mining using data from public databases. Methods RNA sequencing (RNA-Seq) was performed to detect the different gene expression patterns in the human TNBC cell line HS578T treated with docetaxel or doxorubicin. Sequencing data were further analyzed by the R package “edgeR” and “clusterProfiler” to identify the profile of differentially expressed genes (DEGs) and annotate gene functions. The prognostic and predictive value of DDIT4 expression in patients with TNBC was further validated by published online data resources, including TIMER, UALCAN, Kaplan–Meier plotter, and LinkedOmics, and GeneMANIA and GSCALite were used to investigate the functional networks and hub genes related to DDIT4, respectively. Results Through the integrative analyses of RNA-Seq data and public datasets, we observed the overexpression of DDIT4 in TNBC tissues and found that patients with DDIT4 overexpression showed poor survival outcomes. Notably, immune infiltration analysis showed that the levels of DDIT4 expression correlated negatively with the abundance of tumor-infiltrating immune cells and immune biomarker expression, but correlated positively with immune checkpoint molecules. Furthermore, DDIT4 and its hub genes (ADM, ENO1, PLOD1, and CEBPB) involved in the activation of apoptosis, cell cycle, and EMT pathways. Eventually, we found ADM, ENO1, PLOD1, and CEBPB showed poor overall survival in BC patients. Conclusion In this study, we found that DDIT4 expression is associated with the progression, therapeutic efficacy, and immune microenvironment of patients with TNBC, and DDIT4 would be as a potential prognostic biomarker and therapeutic target. These findings will help to identify potential molecular targets and improve therapeutic strategies against TNBC.

Noeli M. Liston Andrade Ferreira, Isabel Umbelina Ribeiro Cezareti, Elieti Romão Nobre Erhart

Com o objetivo de verificar se os enfermeiros que trabalham em Unidades de oncologia se sentem preparados para assistir o paciente com câncer, tendo como base os conhecimentos e habilidades adquiridos no Curso de Graduação em Enfermagem, as autoras realizaram este estudo. Constataram que a formação recebida pelos enfermeiros que atuam na área de cancerologia deixou a desejar, tanto no aspecto do conteúdo teórico e prático que é ensinado nas escolas quanto na metodologia adotada para o ensino desta especialidade. O estudo reforçou a necessidade de que sejam colocadas em prática as “diretrizes para o ensino de cancerologia nos cursos de Graduação em Enfermagem”, conforme preconizado pelo Ministério da Saúde.

Pei-Fei Liao, Ping-Yu Wang, Tzu-Rong Peng

<b>Objective</b>: The purpose of this study was to evaluate the efficacy and safety of programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitors for the treatment of metastatic urothelial carcinoma (mUC). <b>Methods:</b> A literature search was conducted of PubMed, EMBASE, and the Cochrane Library and was limited to the English literature. Randomized controlled trials (RCTs) published up to July 2022 were considered for inclusion. The outcomes were progression-free survival (PFS), overall survival (OS), objective response rate (ORR), and grade ≥ 3 treatment-related AEs (TRAE). Subgroup analysis was performed based on the PD-L1 expression status, and the differences between first- and second-line PD-1/PD-L1 inhibitors were estimated. <b>Results:</b> We included five RCTs comprising 3584 patients in the analysis. Compared with chemotherapy alone, the use of PD-1/PD-L1 inhibitors as monotherapy did not significantly prolong OS [hazard ratios (HR), 0.90; 95% CI, 0.81–1.00] or PFS (HR, 1.12; 95% CI, 0.95–1.32). However, the PD-1/PD-L1 inhibitor combined with chemotherapy significantly improved both OS (HR, 0.85; 95% CI, 0.74–0.96) and PFS (HR, 0.80; 95% CI, 0.71–0.90). Additionally, subgroup analysis showed that in mUC with PD-L1 expression ≥ 5%, treatment with the PD-1/PD-L1 inhibitor alone did not reduce the risk of death. Safety analysis showed that the PD-1/PD-L1 inhibitor alone did not significantly increase the incidence rates of grade ≥ 3 TRAEs. <b>Conclusions:</b> The results show that use of the PD-1/PD-L1 inhibitor alone as first-line treatment is similar to chemotherapy in terms of both survival and response rates. However, the PD-1/PD-L1 inhibitor plus chemotherapy has a significant benefit in terms of PFS or OS. Nonetheless, more RCTs are warranted to evaluate efficiency and safety in the combination regimen of chemotherapy and PD-1/PD-L1 inhibitors.

Naveen Salins

Oliver Piercey, Jeanne Tie

The management of locally advanced rectal cancer (LARC) requires multimodality treatment, typically with neoadjuvant chemoradiotherapy (CRT) followed by total mesorectal excision. However, the treatment landscape is rapidly evolving with total neoadjuvant therapy and non-operative management for selected patients emerging as other novel treatment approaches. With so many treatment options, there is a need for biomarkers to direct a more personalised treatment strategy for patients with LARC. In this review, we summarise the available data regarding the use of circulating tumour DNA (ctDNA) in patients with LARC, as both a marker of treatment response to neoadjuvant therapy and as a marker of minimal residual disease (MRD) after patients have completed definitive local treatment. To date, the ability of ctDNA status to predict for pathologic complete response at any timepoint during multimodality treatment has been variably reported. The most consistent finding across available studies is the ability of ctDNA to detect MRD after CRT and surgery, the presence of which confers a significantly poor prognosis, with increased risk of cancer recurrence and worse overall survival. It is yet to be determined if providing additional therapies to patients with MRD improves outcomes. The available studies assessing the potential utility of ctDNA in LARC are limited by significant heterogeneity in the choice of ctDNA assay, timepoint at which ctDNA was collected, treatment that patients received and length of follow-up, leading to uncertainties about how to implement it into daily clinical practice. As the treatment landscape evolves, larger randomised trials assessing the role of ctDNA in LARC are needed.

Khafizov M.M., Baikov D.E., Akhmadeeva L.R.

Cancer is one of the most important global health problems today, and lung cancer plays a key role in this context. In Russia, more than 50,000 new cases of lung cancer are detected annually, and more than 54% of patients die from this disease in the first year after diagnosis. Computed tomography and radiography are the leading methods for diagnosing lung pathologies, including those of a tumor nature. Existing difficulties in the timely and high-quality detection of these diseases, their differential diagnosis according to various methods of radiation diagnostics, necessitate the use of special research methods. The purpose of the study was to compare the diagnostic potential of computed tomography and SPECT/CT with 99mTc-MIBI in visualization and differential diagnosis of lung malignancies by retrospectively analyzing studies of five patients with histologically verified non-small cell lung cancer. A quantitative analysis of SPECT/CT images was carried out, and the nature of accumulation and washout of the contrast agent in series of dynamic computed tomography in the areas of interest was assessed. Conclusions - SPECT with 99mTc-MIBI and dynamic computed tomography of the lungs make it possible to identify radiographic patterns typical of malignant formations, as well as to study the functional features of blood flow inside the formation. These methods, with their ability to identify characteristics of malignant blood flow in tumors, are increasingly finding application in oncology, including lung tumors, and can be used to distinguish between benign and malignant neoplasms in the lungs, early prognosis and monitoring the response to antitumor therapy.

Cheng Zeng, Jian Zhang

Background and Objective Breast cancer is a highly heterogeneous disease. Its incidence rate is increasing year by year and the mortality rate is the highest in female malignant tumors. Even patients with the same clinical stage and pathological grade have different response to treatment and postoperative recurrence risk. Although the prognosis of breast cancer in China has been gradually improved, there is still a certain gap compared with the 5-year survival rate as high as 89% in developed countries. In recent years, with the continuous enrichment of molecular sequencing data of breast cancer, gene detection technology has important reference value in prognosis judgement and guiding treatment of early breast cancer. This article reviews the current application and latest progress of genetic tests in comprehensive treatment for breast cancer, with a view to promote the precise treatment of breast cancer in clinical practice. Methods We conducted searches using the MeSH terms ‘breast neoplasms’ and ‘genetic testing’ in the PubMed databases from root to 22 January 2021. We conducted an additional search in the National Comprehensive Cancer Network (NCCN) and American Society of Clinical Oncology (ASCO) guidelines to obtain additional information. The search was limited to English, Dutch, French and German articles and research involving humans. Out of the references screened, 51 articles were found eligible for inclusion finally. Key Content and Findings The article reviews the mechanisms and clinical trials of five genetic tests including Oncotype Dx, Mammaprint, Endopredict, mRNA expression of 50 genes (PAM50) and breast cancer index (BCI) in comprehensive treatment for breast cancer. All these tools have been proved to have prognosis value, but only two of them, Oncotype Dx and Mammaprint, are recommended as predictive tools for chemotherapy by National Comprehensive Cancer Network (NCCN) and the American Society of Clinical Oncology (ASCO). Conclusions In order to promote the comprehensive treatment of breast cancer to “precision” and “individualization” for further development, people have extensively researched on multigene testing technology represented by Oncotype Dx, Mammaprint, Endopredict and mRNA expression of 50 genes (PAM50) and breast cancer index (BCI). Each of these five tools has its advantages and limitation, which must be weighed in a wise application.

T. Grushina, I. I. Orlov

Extracorporeal shock wave therapy (ESWT) is a relatively new branch of physiotherapy. PURPOSE OF THE STUDY Conduct an analytical review of the available literature data on the use of ESWT in oncology. MATERIAL AND METHODS A review was conducted, including data from electronic databases: Scopus, Web of Science, MedLine, World Health Organization, The Cochrane Central Register of Controlled Trials, ScienceDirect, US National Library of Medicine National Institutes of Health, PubMed, Google Scholar, elibrary, CyberLeninka, disserCat. RESULTS AND CONCLUSION The study of ESWT in oncology is carried out in two directions: 1) impact on the tumor with the aim of its disintegration, inhibition of growth, enhancement of the action of radiation and/or chemotherapy; 2) rehabilitation of cancer patients. Shock waves in vitro and in vivo significantly reduce the viability and activate apoptosis of cell lines of osteosarcoma, cancer of the stomach, colon, rectum, bladder, breast, urothelial cancer of the upper urinary tract, adenocarcinoma of the cervix, Burkitt's lymphoma, sarcoma, anaplastic thyroid cancer glands, glioblastoma multiforme. Shock waves also sensitize tumor cells for adjuvant chemotherapy and increase its antitumor activity. The lack of a stimulating effect on a number of malignant tumors in this physical factor makes it possible to conduct ESWT studies in the rehabilitation of cancer patients. The data obtained by a number of authors indicate the clinical efficacy of ESWT in the rehabilitation of patients with erectile dysfunction after radical prostatectomy, with postmastectomy lymphedema of the upper limb, with myofascial pain syndrome after cervical lymph node dissection due to malignant neoplasms of the head and neck, with peripheral polyneuropathy induced by cytostatics. However, in order to develop indications and contraindications for the appointment of ESWT in the rehabilitation of cancer patients, it is not enough just to evaluate its clinical effectiveness; currently absent scientific studies with long-term follow-up of patients who received this method of physiotherapy are needed.

M. Kropotov, L. Yakovleva, L. Zhukova et al.

Introduction. Probability of development of multiple primary tumors in patients who received treatment due to head and neck cancers varies between 5.6 and 35.9 % per different sources. moreover, treatment capabilities are severely limited by postoperative anatomical changes and previous radiation therapy, and the second tumor frequently causes death in these patients.The study objective is to identify the epidemiological features of the development of synchronous and metachronous primary multiple tumors in the head and neck.Materials and methods. The article analyzes data on 103 patients with multiple primary tumors who received treatment due to tumors of the head and neck between 1991 and 2020 at the N.N. Blokhin National medical Research Center of Oncology and A.S. Loginov Moscow Clinical Scientific Center.Results. During the study, typical locations of metachronous tumors in patients who received treatment due to primary malignant tumors of the head and neck were determined, duration of development of multiple primary tumors, treatment methods and survival rates were analyzed.Conclusion. Due to high risk of multiple primary tumors in patients who received treatment due to malignant tumors of the head and neck in the next 5 plus years, it is expedient to observe these patients during their whole lifetime. Considering typical locations of metachronous tumors, examination during dynamic observation should include instrumental methods such as panendoscopy. Surgical treatment should involve the whole spectrum of minimally invasive interventions including CO2 laser surgery and transoral robot-assisted interventions.

V. I. Gorinsky, V. Salautin, N. Pudovkin et al.

The spread of oncological diseases is currently one of the main problems in both humanitarian and veterinary medicine. Despite the high achievements of domestic and foreign scientists of modern veterinary medicine in the field of diagnosis, treatment and prevention of oncological processes, the number of cancer-affected animals is quite large and continues to grow steadily. Therefore, improving the complex of diagnostic studies for neoplasms among dogs and cats is one of the priority areas of veterinary medicine. The research was conducted on the basis of the veterinary clinic of the Center for Animal Beauty and Health "Zoostyle" IP Gorinsky V.I. (Volgograd) and the Department of "Morphology, Pathology of Animals and Biology" of the Saratov State Agrarian University. In the period from 2018 to 2021, 244 patients, including 127 dogs and 117 cats, were examined by an oncologist at the veterinary clinic of the Zoostyle Center for Animal Beauty and Health.All the animals belonged to residents of the city of Volgograd. When an animal was admitted to the clinic for an oncological appointment, animals with any visual signs of a neoplasm in the projection of the breast were selected for research. As a result of the physical examination, based on the results of laboratory, X-ray and ultrasound examinations, MR tomography, it was found that breast tumors (OMJ) are more common among dogs and cats. In the population of dogs, OMH accounted for 33.8% (n=43) and 62.4% (n=73) of all cases of oncological pathology in cats. Depending on the gender, breast neoplasia was observed in females - 100%, in cats, females accounted for 89%, and males - 11%. The results obtained indicate that the introduction of a complex of modern high-tech diagnostic methods into veterinary oncology practice is a key element that significantly affects the prospects for providing specialized care and prognosis.

Anastasios I. Manettas, Panagiotis Tsaklis, Dario Kohlbrenner et al.

Rationale: Allogeneic hematopoietic stem cell transplantation (HSCT) is associated with increased treatment-related mortality, loss of physical vitality, and impaired quality of life. Future research will investigate the effects of multidisciplinary rehabilitative interventions in alleviating these problems. Nevertheless, published studies in this field show considerable heterogeneity in selected outcomes and the outcome measurement instruments used. The purpose of this scoping review is to provide an overview of the outcomes and outcome measurement instruments used in studies examining the effects of rehabilitative interventions for patients treated with allogeneic HSCT. Methods: We conducted a scoping review that included randomized controlled trials, pilot studies, and feasibility studies published up to 28 February 2022. Results: We included <i>n</i> = 39 studies, in which <i>n</i> = 84 different outcomes were used 227 times and <i>n</i> = 125 different instruments were used for the measurements. Conclusions: Research in the field of rehabilitation for patients with haematological malignancies treated with allogeneic HSCT is hampered by the excess outcomes used, the inconsistent outcome terminology, and the inconsistent use of measurement instruments in terms of setting and timing. Researchers in this field should reach a consensus with regard to the use of a common terminology for the outcomes of interest and a homogeneity when selecting measurement instruments and measurement timing methods.